Stage IVA Cervical Cancer Clinical Trial
Official title:
A Phase 2 Study of Triapine® (NSC #663249) and Cisplatin in Combination With Pelvic Radiation for Treatment of Stage IB2-IVa Cervical Cancer or Stage II-IV Vaginal Cancer
This phase II trial is studying how triapine and cisplatin given together with radiation therapy works in treating patients with cervical cancer or vaginal cancer. Triapine may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Radiation therapy uses high-energy x-rays to kill tumor cells. Giving triapine together with cisplatin may make tumor cells more sensitive to radiation therapy.
PRIMARY OBJECTIVES:
I. To determine three-month fasting F-18 fluorodeoxyglucose (FDG) positron emission
tomography (PET/CT) imaging complete metabolic response as defined by the European
Organization for Research and Treatment of Cancer (EORTC) PET study group.
SECONDARY OBJECTIVES:
I. To determine 6-month progression-free survival rate as calculated from the date of first
treatment until date of disease progression, relapse, or death.
II. To quantitate change in pre-treatment standard uptake value (SUV) on PET/CT and
post-treatment PET/CT or disease progression PET/CT.
III. To quantitate pre-treatment, during treatment and 3-mo post-treatment grade 2 or higher
gastrointestinal, genitourinary, and sexual function toxicity resulting from Triapine®,
cisplatin, and radiation therapy as measured by CTCAE v3.0, which will be utilized until
December 31, 2010; CTCAE v4.0 will be utilized beginning January 1, 2011.
IV. To associate smoking habit (non-smoker, smoker who quit during therapy, smoker) with 3-mo
post-treatment PET/CT metabolic response and 3-mo best overall clinical response as measured
by RECIST criteria after Triapine®, cisplatin, and radiation therapy.
V. To associate HPV or non-HPV sub-type cervical cancer with 3-mo post-treatment PET/CT
metabolic response and 3-mo best overall clinical response as measured by RECIST criteria
after Triapine®, cisplatin, and radiation therapy.
OUTLINE: This is a multicenter study. Patients are stratified according to brachytherapy
treatment (planned intracavitary brachytherapy vs none).
Patients receive cisplatin IV over 90 minutes on days 2, 9, 16, 23, and 30 and triapine IV on
days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26, 29, 31, and 33. Patients also undergo pelvic
external beam radiotherapy 5 days a week during weeks 1-5. Patients may undergo parametrial
boost radiation and intracavitary low-dose or high-dose rate brachytherapy as clinically
indicated.
Patients undergo whole-body F-18 fluorodeoxyglucose-PET/CT imaging at baseline, at 3 months
after completion of study treatment, and at disease progression. Patients complete Sexual
Function-Vaginal Changes Questionnaire and a smoking behavior questionnaire at baseline, at 3
months after completion of study treatment, and at disease progression.
After completion of study treatment, patients are followed periodically for up to 5 years.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00416455 -
Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT00054444 -
Radiation Therapy and Chemotherapy in Treating Patients With Locally Advanced Cervical Cancer
|
Phase 1 | |
Completed |
NCT01846520 -
Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers
|
N/A | |
Completed |
NCT00068549 -
Radiation Therapy Plus Cisplatin and Gemcitabine in Treating Patients With Cervical Cancer
|
Phase 1 | |
Completed |
NCT00559377 -
FDG and FMISO PET Hypoxia Evaluation in Cervical Cancer
|
Phase 2 | |
Completed |
NCT01079832 -
Stereotactic Radiosurgery Using CyberKnife in Treating Women With Advanced or Recurrent Gynecological Malignancies
|
Phase 2 | |
Completed |
NCT02164461 -
Axalimogene Filolisbac (ADXS11-001) High Dose in Women With Human Papillomavirus (HPV) + Cervical Cancer
|
Phase 1 | |
Completed |
NCT00335998 -
Phase I Study of Intravenous Triapine (IND # 68338) in Combination With Pelvic Radiation Therapy With or Without Weekly Intravenous Cisplatin Chemotherapy for Locally Advanced Cervical, Vaginal, or Pelvic Gynecologic Malignancies
|
Phase 1 | |
Recruiting |
NCT03469531 -
Study of Nimotuzumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer
|
Phase 2 | |
Completed |
NCT01155258 -
Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors
|
Phase 1 | |
Completed |
NCT00897442 -
Collecting Tumor Samples From Patients With Gynecological Tumors
|
N/A | |
Completed |
NCT01098630 -
Patient, Physician, and Nurse Factors Associated With Entry Onto Clinical Trials and Finishing Treatment in Patients With Primary or Recurrent Uterine, Endometrial, or Cervical Cancer
|
||
Withdrawn |
NCT01019278 -
Proton Beam Radiation Therapy and Cisplatin in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer and Positive Lymph Nodes
|
Phase 2 | |
Completed |
NCT02646319 -
Nanoparticle Albumin-Bound Rapamycin in Treating Patients With Advanced Cancer With mTOR Mutations
|
Early Phase 1 | |
Completed |
NCT00104910 -
Cetuximab, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer
|
Phase 1 | |
Completed |
NCT00057863 -
Oxaliplatin and Paclitaxel in Treating Patients With Locally Recurrent or Metastatic Cervical Cancer
|
Phase 2 | |
Completed |
NCT01266447 -
Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer
|
Phase 2 | |
Terminated |
NCT00262821 -
Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With Cervical Cancer
|
Phase 3 | |
Completed |
NCT00107445 -
EF5 in Finding Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Cervical, Endometrial, or Ovarian Epithelial Cancer
|
Phase 2 | |
Terminated |
NCT01992861 -
MRI and PET Imaging in Predicting Treatment Response in Patients With Stage IB-IVA Cervical Cancer
|